Toll‐like receptor 4 signaling inhibits malignant pleural effusion by altering Th1/Th17 responses

Toll‐like receptor 4 (TLR4) is involved in multiple malignancies; however, the role of TLR4 in the pathogenesis of malignant pleural effusion (MPE) remains unknown. The objectives of this study were to explore the impact of TLR4 signaling on the development of MPE in a murine model and to define the underline mechanisms by which TLR works. Development of MPE as well as proliferation and angiogenesis of pleural tumor were determined in TLR4–/– and wild type mice. Differentiation of Th1 and Th17 cells as well as their signal transductions was explored. The effects of TLR4 signaling on survival of mice bearing MPE were also investigated. Compared with wild type mice, Th1 cells were augmented, and Th17 cells were suppressed in MPE from TLR4–/– mice. The in vitro experiments showed that TLR4 deficiency promoted Th1 cell differentiation via enhancing STAT1 pathway and inhibited Th17 cell differentiation via suppressing STAT3 pathway. TLR4 deficiency promoted MPE formation and, thus, accelerated the death of mice bearing MPE, whereas intraperitoneal injection of anti‐IFN‐γ mAb or recombinant mouse IL‐17 protein into TLR4–/– mice was associated with improved survival. Our data provides the first definitive evidence of a role for TLR4 signaling in protective immunity in the development of MPE. Our findings also demonstrate that TLR4 deficiency promotes MPE formation and accelerates mouse death by enhancing Th1 and suppressing Th17 response.

[1]  Kyung-Hee Lee,et al.  Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Xiu-Zhi Wu,et al.  Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion. , 2014, American journal of respiratory and critical care medicine.

[3]  Xu Dong Zhang,et al.  Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination , 2014, Autophagy.

[4]  H. Redmond,et al.  Silencing of TLR4 Increases Tumor Progression and Lung Metastasis in a Murine Model of Breast Cancer , 2013, Annals of Surgical Oncology.

[5]  Wei Yang,et al.  FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. , 2013, Acta histochemica.

[6]  Mingli Yuan,et al.  Interleukin 22-producing CD4+ T cells in malignant pleural effusion. , 2012, Cancer letters.

[7]  I. Kalomenidis,et al.  Malignant pleural effusion: tumor-host interactions unleashed. , 2012, American journal of respiratory and critical care medicine.

[8]  Mingli Yuan,et al.  Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion. , 2012, American journal of respiratory and critical care medicine.

[9]  J. Shih,et al.  Survival of lung adenocarcinoma patients with malignant pleural effusion , 2012, European Respiratory Journal.

[10]  C. Dong,et al.  Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation , 2012, Proceedings of the National Academy of Sciences.

[11]  R. Sorrentino,et al.  Lung cancer and Toll-like receptors , 2011, Cancer Immunology, Immunotherapy.

[12]  I. Donaldson,et al.  Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer , 2011, Nature communications.

[13]  F. Vizoso,et al.  Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis , 2010, BMC Cancer.

[14]  Huanzhong Shi,et al.  Generation and Differentiation of IL-17–Producing CD4+ T Cells in Malignant Pleural Effusion , 2010, The Journal of Immunology.

[15]  Jonathan B. Mitchem,et al.  Induction of Th17 Cells in the Tumor Microenvironment Improves Survival in a Murine Model of Pancreatic Cancer , 2010, The Journal of Immunology.

[16]  Chen Dong,et al.  Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. , 2010, Immunity.

[17]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[18]  Masafumi Nakamura,et al.  Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway , 2009, Journal of surgical oncology.

[19]  P. Hwu,et al.  T helper 17 cells promote cytotoxic T cell activation in tumor immunity. , 2009, Immunity.

[20]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[21]  Ming Fang,et al.  Increased expression of Toll-like receptors 4 and 9 in human lung cancer , 2009, Molecular Biology Reports.

[22]  P. Muranski,et al.  Adoptive immunotherapy of cancer using CD4(+) T cells. , 2009, Current opinion in immunology.

[23]  L. O’Neill When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. , 2008, Immunity.

[24]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[25]  V. Rivero,et al.  Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. , 2007, Cancer research.

[26]  Hua Yu,et al.  Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1 , 2007, The Journal of Immunology.

[27]  Nan Li,et al.  TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. , 2007, Molecular immunology.

[28]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[29]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[30]  Hai‐Bo Yang,et al.  CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. , 2005, American journal of respiratory and critical care medicine.

[31]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[32]  Yibang Chen,et al.  Toll-like receptors on tumor cells facilitate evasion of immune surveillance. , 2005, Cancer research.

[33]  Michael T. Lotze,et al.  Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.

[34]  M. Lotze,et al.  Interleukin-17 promotes angiogenesis and tumor growth. , 2003, Blood.

[35]  Z. Tian,et al.  Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. , 2002, The Journal of clinical investigation.

[36]  E. Tartour,et al.  Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. , 2002, Blood.

[37]  Laurie H Glimcher,et al.  A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment , 2000, Cell.

[38]  K. Jiang,et al.  TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-β1 and IL-10 and tumor cells migration. , 2014, Bio-medical materials and engineering.

[39]  Jian Ye,et al.  The role and regulation of human Th17 cells in tumor immunity. , 2013, The American journal of pathology.

[40]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2011, Nature Reviews Immunology.

[41]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.

[42]  S. Akira,et al.  TLR signaling. , 2006, Current topics in microbiology and immunology.

[43]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.